Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02639234
Title Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

lung non-small cell carcinoma

Therapies

FANG vaccine + Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.